SGL Investment Advisors Inc. Takes $326,000 Position in Boston Scientific Corporation $BSX

Key Points

• SGL Investment Advisors Inc. has acquired a new stake in Boston Scientific Corporation, investing approximately $326,000 for 3,182 shares in Q2.
• Boston Scientific reported a 22.8% year-over-year increase in quarterly revenue, totaling $5.06 billion and surpassing estimates, while earnings per share were $0.75, beating expectations by $0.03.
• Several research firms have recently upgraded their ratings on Boston Scientific, with Oppenheimer raising the target price from $118 to $125, reflecting growing analyst confidence in the stock.

SGL Investment Advisors Inc. bought a new stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 3,182 shares of the medical equipment provider's stock, valued at approximately $326,000.

Several other institutional investors also recently added to or reduced their stakes in BSX. Sound Income Strategies LLC boosted its position in shares of Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider's stock valued at $27,000 after acquiring an additional 120 shares during the period. 1248 Management LLC bought a new stake in Boston Scientific in the 1st quarter valued at $26,000. Y.D. More Investments Ltd acquired a new stake in Boston Scientific in the 1st quarter worth $27,000. Oliver Lagore Vanvalin Investment Group bought a new position in shares of Boston Scientific during the 2nd quarter worth about $37,000. Finally, Activest Wealth Management increased its holdings in shares of Boston Scientific by 6,216.7% during the 1st quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider's stock worth $38,000 after purchasing an additional 373 shares during the period. 89.07% of the stock is owned by institutional investors.

Boston Scientific Stock Down 0.6%

Shares of NYSE:BSX opened at $96.73 on Tuesday. The company's fifty day moving average is $102.75 and its 200-day moving average is $102.04. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $109.50. The company has a market capitalization of $143.33 billion, a PE ratio of 57.58, a P/E/G ratio of 2.34 and a beta of 0.61.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm's quarterly revenue was up 22.8% on a year-over-year basis. During the same period last year, the firm posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Equities research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on BSX. Oppenheimer raised Boston Scientific from a "market perform" rating to an "outperform" rating and lifted their target price for the stock from $118.00 to $125.00 in a research report on Monday, September 8th. Leerink Partnrs raised Boston Scientific to a "strong-buy" rating in a report on Monday, June 16th. Jefferies Financial Group restated a "hold" rating on shares of Boston Scientific in a research note on Monday, July 21st. Leerink Partners lifted their price target on shares of Boston Scientific from $127.00 to $128.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 1st. Finally, Barclays boosted their price target on shares of Boston Scientific from $133.00 to $136.00 and gave the company an "overweight" rating in a report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $120.79.

Insiders Place Their Bets

In related news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the sale, the executive vice president directly owned 23,600 shares in the company, valued at $2,469,268. This represents a 42.32% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business's stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $5,231,500.00. Following the completion of the transaction, the executive vice president directly owned 178,342 shares in the company, valued at approximately $18,659,923.46. This represents a 21.90% decrease in their position. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock valued at $17,972,457 over the last quarter. 0.50% of the stock is owned by insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.